Use of the Combination of Sumatriptan and Naproxen in the Acute Treatment of Migraine: Real World Evidence Study

Phase

N/A

Condition

Chronic Pain

Oral Facial Pain

Pain (Pediatric)

Treatment

combination of sumatriptan 85 mg and naproxen 500 mg

Clinical Study ID

NCT06868953

IRCCSSanRaffaeleRoma

Ages 18-65
All Genders
Accepts Healthy Volunteers

Study Summary

This is a multicenter, observational, prospective, real-life study that will be conducted at Headache Centers, aimed at confirming the efficacy and safety of the combination of sumatriptan 85 mg with naproxen 500 mg. The combination of sumatriptan 85 mg and naproxen sodium 500 mg is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients for whom sumatriptan monotherapy is insufficient. In two randomized studies, the sumatriptan/naproxen sodium combination demonstrated significantly greater efficacy (65% of participants-n=1461-reported pain freedom at 2 hours) compared to sumatriptan alone (55%), naproxen sodium alone (44%), or placebo (28%) when used as a late therapy for a single migraine episode in adults. Similar results were observed in a second study (n=1495), with 57% of participants achieving pain freedom within 2 hours after taking the sumatriptan/naproxen sodium combination, outperforming both sumatriptan monotherapy (50%) and naproxen sodium monotherapy (43%), as well as placebo (29%). This superiority was further assessed through sustained pain freedom over 24 hours, with an efficacy of 23-25% in participants treated with the sumatriptan/naproxen combination compared to placebo (7-8%; p<0.001 for both studies) and its individual components (sumatriptan monotherapy: 14%-16%; p=0.009 and p<0.001, naproxen sodium monotherapy: 10%).

In four additional randomized studies, the combination was also found to be effective in menstrual migraine and dysmenorrhea, as well as in cases of poor response or intolerance to triptan therapy. In clinical trials, sumatriptan/naproxen sodium was generally well tolerated, with an overall safety profile similar to that of sumatriptan. The most common adverse events were consistent with those expected for sumatriptan and naproxen sodium.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Migraineurs (age ≥18 years, <65 years) with at least 4 migraine days per monthaccording to ICHD-3 criteria who have been prescribed the combination of sumatriptan 85 mg and naproxen 500 mg;
Signed informed consent as required;
Agreement to comply with all study procedures, including follow-up visits;
Use of a contraceptive method by all participants throughout the study duration.

Exclusion

Exclusion Criteria:

Age <18 years or >65 years
Pregnancy or breastfeeding
Poor knowledge of the Italian language
Comorbidities with other neurological, cardiovascular, hepatic, respiratory,hematological, or autoimmune diseases, or clinically significant laboratoryabnormalities
Inability to distinguish migraine attacks from tension-type headaches
Migraine characterized by mild attacks or attacks that resolve spontaneously within 2 hours
Hemiplegic or basilar migraine
Headache with the use of acute medication on more than 10 days per month in each ofthe 3 months prior to screening
Unwillingness to participate in the study -

Study Design

combination of sumatriptan 85 mg and naproxen 500 mg

April 10, 2025

December 31, 2026

Study Description

Consecutive episodic or chronic migraine adults (with more than 4 migraine days per month) followed at the Headache Centers and have been prescribed at least one dose of sumatriptan 85 mg in combination with naproxen sodium 500 mg for the acute treatment of migraine will be enrolled.

The collection of demographic and clinical characteristics will be carried out through a direct interview using a detailed, semi-structured questionnaire during the screening/baseline visit, when the prescription of the sumatriptan 85 mg and naproxen sodium 500 mg combination for migraine attacks will be issued. The follow-up visit will occur after 12 weeks (+/-14 days) from the screening/baseline visit, the end of study visit will take place after 24 weeks (+/-14 days) from baseline.

Patients will be provided with paper diaries for the following 12 weeks at screning/baseline visit and at the follow up visit (at week 12). The paper diaries from the previous 12 weeks will be collected will be collected at week 12 and at week 24.

The following questionnaires will be administered:

Migraine Specific Quality of Life Questionnaire (MSQ)
Migraine Interictal Burden Scale (MIBS-4)
Headache Impact Test-6 (HIT-6) were administered at baseline/screening visit, at follow-up visit (at week 12) and at the end of study visit.

Throughout the study, any adverse events will be recorded and managed.